3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
17
Melanoma
3
Glioma
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Multiple Endocrine Neoplasia Type 1
2
Diffuse Intrinsic Pontine Glioma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Rhabdoid Tumor
1
Osteitis Deformans
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Mesothelioma
1
Medulloblastoma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Glioblastoma
1
Familial ependymoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Cystadenocarcinoma, Serous
1
Carcinoma, Hepatocellular
1
Interventions
Cyclophosphamide
119
fludarabine phosphate
97
Cytarabine
86
fludarabine
74
Methotrexate
70
Rituximab
68
Busulfan
56
Whole-Body Irradiation
48
Filgrastim
48
Tacrolimus
43
Mycophenolic Acid
43
Antilymphocyte Serum
40
Etoposide
37
Peripheral Blood Stem Cell Transplantation
36
Granulocyte Colony-Stimulating Factor
35
Melphalan
34
Vincristine
33
Alemtuzumab
33
Cyclosporine
32
Clofarabine
30
Azacitidine
30
Dexamethasone
29
Imatinib Mesylate
26
thymoglobulin
25
Doxorubicin
23
sargramostim
22
Lenalidomide
22
Methylprednisolone
20
Stem Cell Transplantation
19
Daunorubicin
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Leukemia
×
ribociclib
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts